Sk Top Bio Startups

INNOVATION PROJECTS
SKOLKOVO FOUNDATION
BIOMEDICAL TECHNOLOGIES CLUSTER

3
ABOUT THE FOUNDATION
Mission
Goals
Ecosystem
Benefits and opportunities for participants
Statistics and facts
Skolkovo industrial partners: first success stories
BIOMEDICAL TECHNOLOGIES CLUSTER
About the Cluster
Innovation Priorities
Achievements
PROJECTS OF PARTICIPATING COMPANIES
CLUSTER CONTACTS
PROJECTS OF PARTICIPATING COMPANIES
IN ALPHABETICAL ORDER
5
6
7
7
8
10
11
12
14
14
15
16
90
94
CONTENTS

5
ABOUT THE
FOUNDATION
Mission
Goals
Ecosystem
Benefits and opportunities for participants
Statistics and facts
Skolkovo industrial partners: first success stories
6
7
7
8
10
11

6
Energy Efficiency
Information Technologies
Biomedical Technologies
Space Technology and Telecommunications
Nuclear&Radiation
Technologies
The mission of the Skolkovo Innovation Center and the Skolkovo Foundation that established it, is to create an ecosystem in Russia conducive to the development of innovations to support cutting edge research and development and then to commercialize the results of such R&D in five priority fields of technological progress.
The Skolkovo Foundation aims to ensure that the Innovation Center can provide facilities for the full cycle of the innovation process including education, R&D, experimental research and design, and commercialization of the results.
The Skolkovo Foundation is creating a model for the development of an innovation-based economy for all of Russia. The Innovation Center serves as proving grounds to test the mechanisms for promoting the practical application of cutting edge ideas proposed by Russian academic and applied research institutions.
SKOLKOVO IS A KEY ELEMENT IN THE SYSTEM OF RUSSIAN DEVELOPMENT INSTITUTES
that seeks to support innovation projects at every stage of development, from when it’s just an idea all the way through sales and marketing, creating a system of continuous support that startups can draw upon as they work on their projects. The Skolkovo Foundation focuses on the pre-seed and seed stages of business development and some of the aspects of the launch stage. Subsequent stages such as business growth and development, IPO and financing are supported by RVС, RUSNANO and VEB, respectively.
THE SKOLKOVO INNOVATION CENTER WAS ESTABLISHED BY FEDERAL LAW NO. 244 DATED SEPTEMBER 28, 2010 «ON THE SKOLKOVO INNOVATION CENTER» AS THE COUNTRY’S RESPONSE TO THE NEW CHALLENGES OF THE GLOBAL ECONOMY: ACCELERATING TECHNOLOGICAL PROGRESS AND RISING COMPETITION FOR KNOWLEDGE AND COMPETENCIES BETWEEN LEADING NATIONS.
education and R&D
experimental design and research
commercialization
of the results
MISSION OF THE
SKOLKOVO FOUNDATION

7
PARTNERS
Industrial partners (major
international and Russian
companies), accredited VC
investors.
PARTICIPANTS
The kernel of the ecosystem, early-stage
high tech startup companies
that have been given the status of
Skolkovo project participants.
EDUCATIONAL
ENVIRONMENT
Skoltech, OpUS,
international and Russian
partner universities.
TECHNOPARK
Laboratory and research
infrastructure.
Infrastructure of Skolkovo
Innovation Center.
The ecosystem consists of the following key elements: startups, R&D centers of the industrial partners,
venture capital investors, the Technopark, the Skolkovo Institute of Science and Technology (Skoltech)
and the infrastructure, i.e. the town of Skolkovo.
ESTABLISHING AN INNOVATION ECOSYSTEM INCLUDES CREATING AND DEVELOPING
EDUCATIONAL, RESEARCH AND ENTREPRENEURIAL ENVIRONMENTS, AS WELL AS THE
PHYSICAL INFRASTRUCTURE OF THE SKOLKOVO INNOVATION CENTER.
SKOLKOVO ECOSYSTEM
SKOLKOVO’S GOAL IS
TO CREATE AN INNOVATION ECO-SYSTEM
CONDUCIVE
TO RESEARCH
AND ENTREPRENEURSHIP
Open University Skolkovo.

8
BENEFITS AND
OPPORTUNITIES
FOR PARTICIPANTS
TAX AND CUSTOMS BENEFITS:
• Social tax* - 14%
• Income tax - 0%
• VAT - 0%
• Property tax - 0%
• Customs tariffs on imported research equipment - 0 %
* Insurance premiums paid by the employer
HOW TO BECOME A PARTICIPANT:
GRANT SUPPORT
ACCESS TO INFRASTRUCTURE AND CONSULTING:
• R&D infrastructure and common use centers, consultations for
applicants for Skolkovo participant status, office leases
• International and national events
• Education and mentoring (OpUS, Skoltech)
HELP WITH RAISING FINANCE AND ACCELERATION:
• VC and angel investors
• Infrastructure and technologies offered by industrial
partners
CANDIDATES
APPLICANT
01
fills out the online form at www.sk.ru
SKOLKOVO FOUNDATION
02
assesses the application based on formal criteria:
а) Have all the necessary information and documents been provided?
b) Is the applicant a Russian legal entity?
с) Does the applicant meet the technology criteria of the Skolkovo Foundation?
EXPERT PANELS
03
assess the project in detail
a) Is it feasible in principle?
b) What significant advantages does it offer over foreign competitors?
c) What is its commercialization potential?
d) Does the project team have the requisite experience to successfully implement the project on the international level?
10 randomly selected experts from a large pool of experts
PARTICIPANT STATUS IS GRANTED TO THE APPLICANT
~ one month

9
A business plan and
an R&D program are
developed, the market is
researched and a search
for investors is initiated
A working prototype is
manufactured, a tech-nical
design is developed
and the concept is
tested
R&D is completed, an
industrial prototype is
developed and pre-clinical
trials and phase I clinical
trials are conducted
R&D and clinical trials are
completed, pilot batches
are manufactured and
trialed
HOW FINANCING IS ALLOCATED
KEY PRINCIPLES FOR GRANT FINANCING
BY THE SKOLKOVO FOUNDATION
Idea
Seed
Early
stage
Advanced
stage
150
850
4
9
up to
up to
up to
up to
Up to100%
Skolkovo
Grant Amount
PROJECT NEEDS MORE
WORK (A MINI-GRANT MAY
BE GIVEN )
REFUSAL WITH EX-OR
PLANATION
Co-Financing Terms
More than 75%
Co-investor
Up to 25%
Skolkovo
GRANT
MEMORANDUM
REVIEW BY THE
FOUNDATION
GRANT
COMMITTEE
APPLICATION
The participant prepares a
presentation in accordance
with the recommended
format and submits it via
sk.ru
The participant submits
the grant memorandum
with appendixes
The Foundation’s ser-vices
check the applica-tion
and have it reviewed
by external experts
Preparation for a
meeting of the Grant
Committee
10 days no more than 90 (+10) days ~ 1,5 months ~ 2 weeks
The Foundation decides
whether the presentation
will be reviewed
The Foundation checks
whether all the neces-sary
information and
documents have been
submitted
The participant is noti-fied
of the results of the
review
The Grant Committee
decides whether to
award a grant
More than
50%
Co-investor
Up to
50%
Skolkovo
Up to
75%
Skolkovo
More than
25%
Co-investor
$ K
$ K
$ M
$ M

10
STATISTICS AND FACTS
5540
applications from
2010 through 2013
484
applications
to register
intellectual property
in 2013
226
approved grants
in 2010-2013
$ 417 M
revenue earned by
participants
in 2012-2013
$ 257 M
in approved
grants
in 2010-2013
$ 91 M
in financing from
external investors
in 2013
10000+
jobs
as of January 1, 2014

11
SKOLKOVO INDUSTRIAL
PARTNERS:
FIRST SUCCESS STORIES
Industrial partners site their R&D centers in Skolkovo and act as startups customers, thereby
integrating the R&D and business environment in the Skolkovo ecosystem.
industrial partners
estimated number of people to be employed by the
R&D centers by 2015
estimated total r&d budget through the end of 2015
> 40
> 3 500people
> $ 943 M
SKOLKOVO INDUSTRIAL PARTNERS TODAY
Key Benefits of Skolkovo for Industrial Partners
• Access to the best human resources and cutting edge Russian science: Skolkovo is a good place
to work and thus is a magnet for the best specialists from all over Russia and Moscow.
• It is easy to carry out research and experiments thanks to the concentration of technology and
human resources and cooperation with Skoltech, Russian research institutes, Skolkovo partners.
• Access to cutting edge technologies developed by Skolkovo resident startups, some of which
are being developed with state support.
• Simplified administrative procedures, no bureaucracy or red tape.
• The same tax and customs benefits as those enjoyed by Skolkovo participants.

13
ABOUT THE CLUSTER
About the cluster
Innovation priorities
Achievements
14
14
15

14
Cell or organ image analysis algorithms
Computational systems biology models and methods
Cardio-vascular drugs & diagnostics
Tools for large scale DNA or protein sequence analysis
Cell technologies for development of pluripotent or differentiated cells or tissues
Materials & devices modifying structure, physiology, or development of tissues
(clinical bioengineering)
Anti-viral drugs, vaccines and diagnostics
Molecular modeling tools, molecular interaction models and tools
Neurological drugs & diagnostics
Translational (personalised) medicine, biomarkers
Cancer drugs & diagnostics
Immuno-therapeutics, therapeutics for inflammation
E-health, clinical informatics, and devices for patient monitoring, diagnostics,
and therapeutic indications
Endocrine drugs & diagnostics
ABOUT THE CLUSTER
INNOVATIVE PRIORITIES
The Cluster’s goal is to create a competitive biomedical technologies industry while bearing in mind that, in addition to trying to maximize revenue, we’re making a decisive contribution to improving the nation‘s health.
Our efforts have led to a significant increase in the number of companies seeking to commercialize science and biomedical technologies. As we try to promote this growth, we are seeing that the goal of the companies in our sector is improving healthcare. A healthy nation is a productive nation. Our mission is to support the development of biomedical technologies for a healthy and wealthy Russia.
Kirill Kaem
Vice President,
Executive Director of the BioMedical
Technologies Cluster
of the Skolkovo Foundation

15
ACHIEVEMENTS
The Cluster brings together 238 innovative companies specializing in the development of innovative medicines, medical diagnostic and treatment products, new bio-compatible materials and cellular technology products.
The companies have already created over 400 jobs. The Cluster’s startups generated total revenue of $ 51 K in 2013.
The Cluster has given out 24 grants and 20 mini-grants (5 million rubles or less) for R&D.
Cluster’s residents have been highly successful in their research and development efforts.
• Patent No. 2435783 ‘Chimera Peptide and Pharmaceutical Composition for the Treatment of Cancerous
Conditions’ issued to Skolkovo resident MetaMax was included in the top 100 Russian inventions of 2011, with
the list published by the Federal Service for Intellectual Property (Russian Patent Service).
• The findings of research carried out by OncoMax were presented at the Best Oral Presentations session of
the 5th European Multidisciplinary symposium for urological cancers (EMUC) that was held in Marseilles on
November 15-17, 2013.
• In 2011, Russia’s first ever Prix Galien Award in the Best Research nomination was given to Alexander
Sobolev and Andrey Rosenkrantz from the Institute of Gene Biology of the Russian Academy of Sciences and
Vladimir Lunin (Gamaleya Epidemiology and Microbiology Research Institute) for the Modular Nano-transporter
Technology (MNT) they are working on. MNT can repeatedly increase the efficacy of drugs. Skolkovo-based
company Translek founded in 2011 is working on the commercialization of this technology.
• Hemacore Labs has developed a laboratory prototype of a device and technology for Thrombodynamics-4D
analysis (a new integrated, high-sensitivity hemostasis test that can easily detect disorders of both plasma-
and platelet-mediated stages of blood clotting); a series of experiments were successfully carried out and the
results were presented in an oral presentation at the ISTH-2011 congress (Dashkevich et al, 2011); an article
was published (Dashkevich et al, 2012) and was praised by the editorial staff of Stern magazine (2012).
• Eidos-Medicine has developed a series of robotic surgery simulators and successfully sold its first Surgery
Simulator to the US-based corporation Covidien, one of the largest global manufacturers of medical equipment,
in 2014.
• In March 2014, Fusion Pharma formed the first advisory board in Germany to address the clinical development
of a new candidate drug for the treatment of drug resistant forms of chronic myelogenous leukemia, while at the
2nd congress of Russian hematologists held in Moscow in April 2014 the company presented its findings to the
international scientific community. The congress participants were extremely happy to hear that a breakthrough
drug could be just around the corner. Doctors are in urgent need of a new highly effective and safe drug for the
treatment of this condition.
• Another Cluster resident Incuron, LLC got an FDA approval in 2013 for the clinical trials of the new cancer drug
CBL0137. The company successfully completed phase 1a trials in one year and is now enrolling patients for
Phase 1b trials in the USA.
• Skolkovo resident 3D Bioprinting Solutions opened a laboratory in Moscow that is implementing an innovative
project to develop 3D organ bio-printing. The company was founded by the Independent Laboratory Invitro.
• NovaMedica Innotech, LLC announced the creation of the research center in the Skolkovo Technopark to
contribute to the transfer of pharmaceutical products and technologies to Russia as well as to its in-house
research and development.
• In February 2014, Bind (RUS) opened a new R&D center in Moscow. The company’s laboratories are going to
develop targeted drugs that utilize nano-particles for the treatment of cancers and other conditions.
• At the world’s largest fundamental cancer research congress organized by the American Association of Cancer
Research held in San Diego on April 5-9, 2014, Russian Pharmaceutical Technologies presented the first results
of pre-clinical trials of the new cancer drug RPT835. There was a keen interest at the congress in the new
RPT835 inhibitor.

17
PROJECTS
OF PARTICIPATING
COMPANIES BROKEN DOWN BY INNOVATION PRIORITIES

19
CELL OR ORGAN IMAGE ANALYSIS ALGORITHMS
THE TECHNOLOGY OF 3D ORGANS
BIOPRINTING FROM PATIENT’S
AUTOLOGOUS STEM CELLS
COMPETITIVE ADVANTAGES /
- On-chip reconstruction of a functional nephron from human kidney cells with the basic kidney functions.
- The nephron will be a prototype of an elementary structure for subsequent 3D-bioprinting of a kidney;
- Considerable improvement of the potential nephrotoxicity assessment of new drugs thanks to a new technology, “nephron-on-chip”.
INNOVATION’S MAIN POINT /
Two kidney functions will be reconstructed in the nephron-on-chip: filtration and reabsorption.
Existing or developed study models in 2D-cell models and in animals are insufficiently relevant and suffer a high degree of inaccuracy. Approx. 7% of new medicinal formulas worldwide do not reach the clinical trials stage due to nephrotoxicity discovered during the pre-clinical trials. 93% of the remaining formulas in phase I clinical trials have complications in 30-50% of patients in the form of acute renal failure because of nephrotoxicity.
RESULTS ACHIEVED /
- The initial stage of development.
- A research laboratory has been built and equipped.
- An international team of researchers has been formed. The project combines an intellectual potential and a unique experience of leading experts in the regenerative medicine.
MARKET POTENTIAL/
7% of new medicinal formulas worldwide do not reach the clinical trials stage due to nephrotoxicity discovered during the pre-clinical trials. 93% of molecules in phase I clinical trials have complications in 30-50% of patients in the form of acute renal failure.
THE TEAM /
ALEXANDER OSTROVSKY
PhD (medicine), CEO of the biotechnological research laboratory 3D Bioprinting Solutions; Chairman of the Board of Directors, INVITRO.
VLADIMIR MIRONOV
Scientific supervisor of the biotechnological research laboratory 3D Bioprinting Solutions, PhD(medicine).
SERGEY NOVOSELOV
Head of the researchlaboratory 3D Bioprinting Solutions, Doctor of Biological Sciences.
CONTACTS /
Moscow
Alexander
Ostrovsky
+7 (499) 769-50-18 info@bioprinting.ru smirnova@bioprinting.ru Kashirskoyeshosse, 68,
korp. 2, Moscow, Russia
www.bioprinting.ru
3D BIOPRINTING SOLUTIONS

20
TECHNOLOGY OF EXTREMITY PROSTHESIS MANAGING WITH THE AID
OF BRAIN-COMPUTER INTERFACE
A technology for comfortable noninvasive control by the manipulator (including prosthesis) is under development.
MAIN POINTS OF INNOVATION /
Neural controller will allow to detect volitional impulse to different movements in the patterns of the human brain biological currents and transform them into commands for prosthesis electromechanical actuators. A person will be able to move prosthesis / manipulator with mere intention to action.
ACHIEVED RESULTS /
2013-2014 - The development and improvement of neural controller prototype.
2015-2016 – Release of neural controller into the market.
8 scientific articles in the international and Russian journals have been published.
MARKET POTENTIAL /
Precision of processing and detection of brain signals is up to 95% versus 80 - 85% for the most advanced international interfaces.
THE TEAM /
ALEXANDER KAPLAN,
Doctor of Biological Sciences, Prof.
The project involves an experienced team in the area of neurophysiology, with many years experience in successful research in the field of human neurophysiology at major Russian and foreign specialized centers (Japan, Germany, South Korea).
INNOVATECH
CONTACTS /
Moscow
Alexander Kaplan
+7 (495) 939-13-73
akaplan@mail.ru
www.brain.bio.msu.ru
COMPUTATIONAL SYSTEMS BIOLOGY MODELS ANDMETHODS

21
INFORMATION PLATFORM FOR BIOMEDICAL DATA ANALYSIS AND DEVELOPMENT
OF INNOVATIVE DRUG PRODUCTS
The high modularity of the platform will allow to create a large number of programs covering all areas of bioinformatics and systems biology, necessary to create innovative medication.
Conveyor system «from the genome t
o the drug» for conducting research
in the area of biomedical data analysis and drug discovery with the use of software modules for BioUML platform and experimental validation of the computer forecast.
ACHIEVED RESULTS /
First commercial version of the platform successfully commercialized under the name geneXplain platform has been launched. A prototype of BioStore trading platform has been developed and launched intooperation. 85 research papers have been published in the Russian and international journals.
MARKET POTENTIAL /
The global bioinformatics market will reach $ 8.3 billion in 2014, while the bioinformatics platform market will
be the largest and will be estimated
at $ 3.9 billion.
THE TEAM /
ALEXANDER KEL,
PhD (Biology), CEO.
FEDOR KOLPAKOV,
PhD (Biology), Executive Director.
VLADIMIR POROYKOV,
Doctor of Biological Sciences, Prof., ResearchDirector.
EDGAR VINGENDER,
Prof., Director of Bioinformatics Department,
University Medical Center Gttingen.
ALEXANDER TROPSHA,
Prof. and Deputy Dean for Academic Affairs inEshelman School of Pharmacy, UNC-Chapel Hill, NC, USA.
BIOSOFT.RU
CONTACTS /
Novosibirsk
Alexander Kel
alexander.kel@biosoft.ru
fedor@biosoft.ru
www.biosoft.ru
COMPUTATIONAL SYSTEMS BIOLOGY MODELS ANDMETHODS

23
The most promising and easy-to-use class of anticoagulants. Exceeds all known analogs for human blood plasma activity. Modifications show world-leading values for the most important blood clotting parameters (DD217).
Modeling based on a protein chain structure accounting for physical and chemical properties of the molecule and selection of molecule class accounting for patent non-infringement. Close monitoring of experimental work via computer modeling with instantaneous feedback.
ACHIEVED RESULTS /
DD217 has been studied for acute toxicity, mutagenicity, and subchronic toxicity. A dosage form is indevelopment, stability studies are underway, and a pilot synthesis method is being developed.
MARKET POTENTIAL /
The substance classes have been patented. Development in Russia: has a potential under the Pharma 2020 Strategy. The Russian market of anticoagulants (ATX B01 group) in 2010 was estimated at 6.57 billion rubles (Remedium).
THE TEAM /
DMITRY TOVBIN,
PhD in Physics and Mathematics, CEO;
NIKOLAI TARASOV,
PhD inPhysics and Mathematics, Chief Science Officer;
DMITRY MALAKHOV,
PhD in Chemistry, Chief Chemist;
ARSENY AYBUSHEV,
PhD inPhysics and Mathematics, Programmer/Developer;
VLADIMIR GORSHKOV,
PhD in Chemistry, Chemist;
DMITRY SYCHEV,
Doctor of Medicine, Project Development Consultant.
ORIGINAL NEXT-GENERATION ORAL
ANTICOAGULANT, DIRECT
FACTOR XA INHIBITOR
PHARMADIALL LLC
CONTACTS /
Moscow
Dmitry Tovbin
+7 (903) 761 27 17
dtovbin@didiall.com
ul. Kakhovka, 10, korp. 3
CARDIO-VASCULAR DRUGS & DIAGNOSTICS

24
TECHNOLOGY FOR TREATING ATHEROSCLEROSIS OF HUMAN BLOOD VESSELS USING CHEMICALLY MODIFIED NANOPARTICLES
Chemically modified carbon-containing nanoparticles can be used as coatings for vascular stents, and as the main substrate in columns for extracorporeal blood purification. The solution has lower price and higher efficacy.
Creation of hybrid organic modified nanomaterials with prescribed surface properties. The technology can hybridize under the mildest conditions possible with high efficacy using a simple hardware design.
ACHIEVED RESULTS /
A technology has been developed to synthesize the necessary nanomaterial (carbon-containing nanoparticles with dimensions up to 10 nm); proof of concept has been demonstrated for chemical modification of carbon-containing nanoparticles with lipophilic properties.
MARKET POTENTIAL /
There are no biologically active modified nanoparticles with the given affinity to plaque components currently on the market. Nanoparticles can be used in the production of next-generation coronary and vascular stents.
THE TEAM /
SHAMIL AKHMEDOV,
Project Director;
Scientific Consultants:
VIKTOR FILIMONOV;
SERGEY AFANASYEV;
PAVEL POSTNIKOV;
YANA ANFINOGENOVA;
ANDREY GALANOV.
CONTACTS /
Tomsk
Shamil Akhmedov
ashd@mail.ru
Russia, Tomsk Oblast,
Tomsk,
ul. Ivana Chernykh,52–60
NANOKOR LLC
healty artery
blood flow
narrowed artery
with atherosclerosis
atherosclerotic
plaque

25
HARDWARE AND SOFTWARE
FOR ATHEROSCLEROSIS
AND CARDIOVASCULAR
DISEASEPREDICTIVE GENE TESTING
The new product has no direct analogues. The number of potential users of this service in Russia in 2012 is roughly 35 million people.
The institute is developing a method and predictive gene testingfor atherosclerosis based on analyzing mutations in the mitochondrial genome. Implementing this method results in early diagnostic of atherosclerosis.
ACHIEVED RESULTS /
Scientific research and basic clinical epidemiology studies have been completed, test prototypes ofdiagnostic kits to be used with hardware and software have been developed along with the hardware and software schematic diagram.
MARKET POTENTIAL /
The market for early atherosclerosis predictive gene testing is practically undeveloped, so the market share cannot be determined as of yet.
THE TEAM /
ALEXANDER OREKHOV,
General Director;
IGOR SOBENIN,
Atherosclerosis Treatment Center Director
ALEXANDER FEOKTISTOV,
Biochemical Research Group Lead;
VARVARA OREKHOVA,
Inpatient Clinic Department Manager;
NIKITA NIKIFOROV,
Cell Biology Department Manager.
INSTITUTE FOR ATHEROSCLEROSIS RESEARCH LLC
CONTACTS /
Moscow
Alexander Orekhov
+7 (495) 415 95 94
a.h.opexob@gmail.com
Bagrationovskyproezd, d. 3
www.inat.ru

26
EMC Corporation specialists are participating in the project. A license agreement with Life Technologies is in development to provide special conditions for developing clinical applications for semiconductor sequencing technology.
Integrated automation of the process from loading the sample in the sample prep station through sequencing, analysis, and data interpretation. The project is aimed to achieving the goals of personalized medicine and genomic diagnostics.
ACHIEVED RESULTS /
The Ion PGM semiconductor DNA sequencing system was successfully launched in 2012. Clinical tests have been performed. A software beta version has been developed in conjunction with Reksoft to analyze genomic data.
MARKET POTENTIAL /
The development project comprises a hardware and software complex that allows geneticists to analyze patient’s genomic data.
THE TEAM /
ALEXANDER PAVLOV,
Project Director;
ARSENY SMIRNOV,
Medical GeneticsDirector;
DMITRY POLYNTSEV,
Financial Management;
ANTON BRAGIN,
IT Solutions, GeneticData Analysis Software.
UNIQUE INTEGRATED SOLUTIONS FOR
MOLECULAR GENETIC
DIAGNOSTICS INTENDED TO IMPROVE
PERSONALIZED MEDICINE
SEQUOIA GENETICS LLC
CONTACTS /
St. Petersburg
Alexander Pavlov
+7 (812) 677 65 35
apavlov@alkorbio.ru
192148, Russia, St. Petersburg,
Zheleznodorozhny
Prospekt, 40 A
www.sequoiag.ru
TOOLS FOR LARGE SCALE DNA OR PROTEIN SEQUENCEANALYSIS

27
TOOLS FOR LARGE SCALE DNA OR PROTEIN SEQUENCEANALYSIS
KITS FOR MOLECULAR
DIAGNOSTICS IN ONCOLOGY
The increased sensitivity of the test, the possibility to analyze mutations without biopsy (by blood testing). The possibility of lung cancer testing without bronchoscopy. he possibility of testing patients with unresectable tumors.
Highly-sensitive test of EGFR mutations in blood plasma DNA based on the new version of multiplex polymerase chain reaction (PCR) and allele-specific PCR in real time mode.
ACHIEVED RESULTS /
The project is searching for financing to carry out R&D.
Development of the test technology on the
modelsamples is ongoing. The project is searching for financing to complete R&D.
MARKET POTENTIAL /
The cost of one set production
(running cost after R&D) is 10-15 USD in mass production. Selling price is USD 100-200 (Russia) and USD 500-1,500
(Western Europe).
Possible market share for the Russian manufacturer is 1-3%, i.e., approximately USD 80-200 million per year.
THE TEAM /
ALEXANDER KORNIENKO,
CEO;
SERGEY KOVALENKO,
CSO;
VLADIMIR SHAMANIN,
Head of R&D;
NATALIA MATSENKO,
Research Assistant;
LEV PETRENKO,
Research Assistant.
BIOLINK LLC
CONTACTS /
Novosibirsk
Sergey Kovalenko
+7 (383) 334 86 14 biolink@inbox.ru
Russia, Novosibirsk Region, Novosibirsk,
ul. Timakova, 2
www.biolinklab.ru

28
Lower costs with higher treatment efficiency compared to standard treatment. Absence of the negative systemic effects on the immune system compare to conventional immunosuppressive drugs , absence
of side effects.
We offer a new approach to the Multiple Sclerosis treatment - targeted cell therapy, based on adoptive transfer of deficient autologous T cells with immuno suppressive ability. Compensation of deficiency of the regulatory Т cells in patient. Patented way of autologous regulatory T-cell expansion provides
a 1000-1500-fold increase in the number of cells within a short period of time
(7 days). The vitality and full capacity of expanded cells is proved.
ACHIEVED RESULTS /
• Technology developed and patented.
Patent RU 2437933C1, US Patent 8,697,060 B2
International Patent Application claiming priority to RU 2012127158;
• POC in human: Multiple Sclerosis -
14 patients : safe, no side effects, prevent relapses; EDSS stabilized over two years;
MARKET POTENTIAL /
Disabling and fatal disease, patients aged 20-50 years. The Costs of treatment ~$25000 per year. More than 2.5 million people worldwide suffer from multiple sclerosis. Total number of patients with autoimmune diseases is more than
40 million. This therapy also can be effective in the treatment of other autoimmune diseases: rheumatoid arthritis, SLE, diabetes type I, psoriasis, etc.
THE TEAM /
SVETLANA BYKOVSKAYA,
MD, Prof., CEO, Project Research Manager;
YEVGENY NASONOV,
MD, PhD, scientific consultant;
ANASTASIA LOCHONINA,
the scientist.
AUTOLOGOUS T-REGULATORY CELL VACC INE FOR AUTOIMMUNE DISEASES TREATMENT WITHOUT TOTAL IMMUNE SUPPRESSION
REGENEX
CONTACTS /
Moscow
Svetlana Bykovskaya
+7 (916) 436 22 91
Sbykovskaia@gmail.com
www.roscardioinvest.ru
CELL TECHNOLOGIES FOR DEVELOPMENT OF PLURIPOTENTOR DIFFERENTIATED CELLS OR TISSUES

29
The optimal combination of physical chemistry, mechanics, technology, and biomedicine parameters of “tissue bioconstructors” will improve the efficacy of regenerative medicine, create a new class of implants, and expand the spectrum of medical services.
Improvement of medical implants. Biomedical parameters, biomechanical material properties, and processes at the artificial material–biological tissue interface are important for successful grafting and functioning of implants.
ACHIEVED RESULTS /
Clinical trials of the product are underway. Test prototypes have been produced. The team is searching for co-investors and partners.
MARKET POTENTIAL /
The resulting implants have a wide range of applications in orthopedics, stomatology, surgery, etc.
THE TEAM /
IGOR KHLUSOV,
CEO;
YURI DEKHTYAR.
PROJECT PARTNERS:
Siberian State Medical University (Tomsk);
Riga Technical University (Latvia);
Institute of Strength Physics and Materials Science of the Siberian Branch of the Russian Academy of Sciences;
Biology Department at Lomonosov Moscow State University.
CONCEPT AND IMPLEMENTATION OF «TISSUE BIOCONSTRUCTOR» TECHNOLOGIES
IN REGENERATIVE MEDICINE
BIOKONSTRUKTOR-S LLC
CONTACTS /
Tomsk
Igor Khlusov
+ 7 (913) 823 39 62
khlusov63@mail.ru
Russia, Tomsk Oblast,
Tomsk,
ul. Sibirskaya, 31,
apt. 319

30
DENDRIVAX ANTICANCER VACCINE BASED
ON DENDRITIC CELLS WITH A NEW
GENERATION ADJUVANT
The novelty of the approach is to activate dendritic cells (DCs) in situ and to use allogeneic cell adjuvant that stimulates a cytotoxic T-cell response, which reduces the costs and increases the effectiveness of the vaccine.
Development and introduction into clinical practice of DendriVax immunotherapeutic vaccine based on DCs with a new generation adjuvant for treatment of hormone-resistant prostate cancer and other solid tumors.
ACHIEVED RESULTS /
A pilot clinical trials have been conducted in Philippines and in the United States to prove basic technology. The concept of a new generation adjuvant was developed and patented. The plan of transfer and scaling of core technology in Russian Federation has been formulated.
MARKET POTENTIAL /
A real alternative to chemotherapy will appear in the market for treatment of stage III-IV prostate cancer, increasing life expectancy and improving patients’ quality of life.
THE TEAM /
OLEG EGOROV,
CEO;
VASILIY OSCHEPKOV,
Medical Director;
IRINA BALDUEVA,
Head of the Production Laboratory, Chief
Investigator;
BENJAMIN TJOA,
Production Expert;
WILLIAM CAVANAGH,
Clinical Trial Expert;
MIKHAIL KISELEVSKIY,
Dr. Bio. Sc., Prof., Scientific Consultant
CONTACTS /
Moscow
Oleg Egorov
vlad.v.egorov@gmail.com
115419, Russia, Moscow,
ul. Ordzhonikidze, 11,
build. 2
MEDVIO EURASIA LLC

31
The proposed technology is highly competitive due to original patents for cell culture technique and test systems developing.
Creation of hereditary neurodegenerative diseases cell models and test systems (based on iPS cells) for normal specialized human cells drugs creening using the company’s new technology.
ACHIEVED RESULTS /
The company studies genetic components of the pathologies of hereditary neurodegenerative diseases for which there are currently no effective treatments.
MARKET POTENTIAL /
Currently there are no development of original drugs in Russia, which is why the main target is the global pharmaceutical development market.
THE TEAM /
ROMAN DEEV,
General Director;
ILYA BOZO,
Research Scientist.
PROJECT PARTNERS:
HSCI OJSC (Human Stem Cells Institute)
TEST SYSTEMS FOR DISEASE
PATHOGENESIS STUDYING
AND DRUG DEVELOPING
NEXTGEN LLC
CONTACTS /
Moscow
Roman Deev
+7 (965) 147 12 77
bozo.ilya@gmail.com
ul. Gubkina, d. 3, korp. 1
www.hsci.ru/o-kompanii/
struktura-gruppy-iskch

32
ZEDIGUS - TECHNOLOGY OF THE
PRODUCTION OF TARGETED «SMART» DRUGS FOR THE TREATMENT OF PURULENT
AND GUNSHOT WOUNDS AND DIABETIC FOOT
Targeted delivery and retention of antibiotics in the focal point of wound infection. Overcoming of the development of multidrug-resistant pathogens, which cause the development of wound infection.
Application of integration of technologies (nano-, bio-, and engineering) to create innovative drug molecules -biointerface effect.
ACHIEVED RESULTS /
The first samples of the unique ointment were obtained that demonstrated the effectiveness in the treatment of severe and complicated injuries, including septic, gunshot, diabetic foot, venous ulcers and non-healing ulcers in cancers.
MARKET POTENTIAL /
The volume of sales of ointments in Russia was 9.1 bln rubles in whole sale prices in 2011. Sales volume reached 218.5 mln packages in physical term (+17.0% compared to 2010) (IMS Health).
THE TEAM /
MIKHAIL EPINETOV,
Doctor of Medicine , Prof., CEO;
VALERY MIKHAILOVICH DEMBITSKY,
Doctor of Chemical Science, Prof., Pharmachemist-Technologist;
NIKOLAI LVOVICH SHIMANOVSKY,
Doctor of Medicine, Prof., Molecular Pharmacologist;
VLADIMIR VITALIEVICH MELNIKOV,
Doctor of Medicine, Prof., Surgeon- Researcher.
CONTACTS /
Astrakhan
Mikhail Epinetov
+7 (8512) 34 23 21
epinetov@mail.ru
info@astlek.com
Russia, Astrakhan Region,
Astrakhan, ul. Tatishcheva,
20, block. A, of. 415
www.astlek.com
SCIENTIFIC – PRODUCTION MEDICAL AND PHARMACEUTICAL ESTABLISHMENT «ASTLEK» LLC
MATERIALS & DEVICES MODIFYING STRUCTURE,PHYSIOLOGY, OR DEVELOPMENT OF TISSUES(CLINICAL BIOENGINEERING

33
DEVELOPMENT OF A LASER SYSTEM FOR
MINIMALLY INVASIVE SURGERY
Incision of biological tissues within the accuracy of 50 microns,
Absence of bleeding,
It does not cause thermal damage to the tissue cells;
It possesses potent sterilizing effect;
It reduces the time of operation,
Scar tissue is not formed at the site of the incision.
An unique method was developed of minimally invasive surgeries by cold ablation of biological tissues with laser radiation energy to the desired depth controlled by a physician in the conditions of complete hemostasis, as well as a laser system for its implementation.
ACHIEVED RESULTS /
The prototypical 2940 nm laser has diode pumping and transmission of laser radiation through ZBLAN optical fiber to the operated tissue. Cold ablation of tissues without their thermal damage was carried out in vitro.
MARKET POTENTIAL /
During surgery, the effective incision or evaporation of abnormal tissue is provided without signs of heat damage with the simultaneous cessation of bleeding. These results were never achieved before.
THE TEAM /
NADEZHDA FASHUTDINOVA,
Project Manager, Company Director;
OLEG KUZMIN,
Head of R&D;
OLGA RISOVANNAYA,
Medical Research Program Manager.
8 engineers, 2 technicians with experience in the development of laser equipment for civilian and military applications are involved in the implementation of the project.
CONTACTS /
Krasnodar
Oleg Kuzmin
+7 (988) 246 96 46
kuzmin@photonics-biotech.com
350063, Russia, Moscow, ul. Komsomolskaya, 13
LASER BIOMED LLC

34
CONTACTS /
St. Petersburg
Alexander Malygin
+7(812)328 42 51 malygin.av@gmail.com 191186, Russia, St. Petersburg,
NevskyProspekt, 30
Improves the hearing in 89% of patients with sudden and acute hearing loss and 67% of patients with chronic hearing loss, regardless of cause. Tinnitus ceases or lessens in 91% of patients.
An unique patented technologyofaudioselectivetranscranial electric stimulation of protective (endorphin) mechanisms of the brain using pulse current in conjunction with acoustic impact on the acoustic organ with tonal signals at the hearing loss frequencies.
ACHIEVED RESULTS /
A line of devices has been produced based on the fundamental technology for treating disorders of various etiologies. Development of a method of treating sensorineural hearing loss has begun based on TES therapy in conjunction with acoustic impact.
MARKET POTENTIAL /
The audiology equipment market will reach 26.2 billion dollars by 2017 (Audiological Devices -Global Strategic Business Report). The US market of mobile medical devices is 15 million devices (HIMSS Analytics).
THE TEAM /
ALEXANDER MALYGIN,
PhD in Engineering, CEO;
VALERY LEBEDEV,
Doctor of Medicine, Professor, RANS Academician,
Science Division Director;
DMITRY TSEITLIN,
PhD inMedicine, Clinical Trials and Commercialization Director;
ANNA BELIMOVA,
PhD inMedicine, Audiologist.
PROJECT PARTNERS: TES Center LLC
MOBILE TECHNOLOGY FOR
TREATING SENSORINEURAL
HEARING LOSS AND TINNITUS
TES MOBILE LLC

35
The valve has three cusps, which will ensure the axial blood current, thus creating conditions close to the physiological ones. Improves patient’s quality of life, reduces anticoagulant consumption, noise level, blood hemolysis and the likelihood of repeated implantation.
A novel tricuspid cardiac valve combines the advantages of mechanical and biological valves. The major advantage of the tricuspid cardiac valves is the availability of the axial blood current, which reduces the thrombus formation rate.
ACHIEVED RESULTS /
The functional and robustness parameters undergo preliminary testing.
Clinical trials of the product are planned, coupled with physical and chemical studies of materials and with the refinement of engineering processes.
MARKET POTENTIAL /
A marketing authorization from the Federal Service for Supervision of Healthcare and Social Development has been obtained, permitting manufacture, sales and application of the new tricuspid cardiac valve Tricardis.
THE TEAM /
ALEXANDER SAMKOV,
PhD in Engineering, CEO;
REGINA KEVORKOVA,
mechanical engineer, deputy CEO for science;
ANTONINA MAKEEVA,
electronics engineer, commercial manager.
DEVELOPMENT OF SKL - AN INNOVATIVE TRICUSPID BIOMECHANICAL
ARTIFICIAL CARDIAC VALVE USING
POLYMERIC COMPOSITE MATERIAL
EMITRON LLC
CONTACTS /
Moscow
Alexander Samkov
+7 (499) 127 46 06 roscardioinvest@ yandex.ru Bldg. 1, 20 Nagornayaul., 117186 Moscow, Russia www. roscardioinvest.ru

36
CONTACTS /
Moscow
Pavel Zaburski
+7 (916) 706 77 12
zaburski@inbox.ru
Bldg. 2, 4 Verbnayaul.,
107143 Moscow, Russia
www.abiotex.ru
DEVELOPMENT OF DENTAL IMPLANT
COATING THAT WILL STIMULATE
OSTEOGENY AND PROVIDE
TARGETED IMPACT ON REGENERATION
PROCESSES IN PERIIMPLANT TISSUES
The haemostatic activity may partially or fully lift restrictions on traditionally absolute counterindications to implants of patients with idiopathic or symptomatic violations of the blood coagulability function.
The coating being developed is a combination of biologically active ingredients. The substances that are components of the coating exert direct influence in the precursor cells, thereby inducing osteogeny in the implantation area.
ACHIEVED RESULTS /
A material of titanium-made surface coating has been obtained that contributes to osteointegration and displays bactericidal properties. The technology of applying an organic coating onto titan is being refined.
MARKET POTENTIAL /
To date, the Russian implantology market is evaluated at 500,000 implants per year. The Russian market shows a tremendous demand for high-quality implant services.
THE TEAM /
PAVEL ZABURSKI,
CEO;
ILYA FRIDMAN,
co-founder of Alpha Biotech LLC;
OFIR FROMOVICH,
consultant for major development areas and evaluation of declared parameters;
SERGEY KISELEV,
head of technology and engineering solutions department;
MIKHAIL YASINOV,
research fellow.
ALPHA BIOTECH LLC

37
Jointech™ synovial shunt is a new method of treatment of knee joint effusion. It is implanted in a minimally invasive way with by means of specially developed minimally invasive delivery system.
A synovial shunt is an implant made of nitinol alloy with self-retaining mounts on two opposite sides of the implant. This allows the implant to remain in a fixed position within the joint after implantation.
ACHIEVED RESULTS /
Clinical trials were carried out by European standards. Technical and regulatory documents are prepared. The possibility of using of Jointech™ synovial shunt in patients is being assessed.
MARKET POTENTIAL /
Only in 2010 over 4,000,000 arthroscopies were performed in the USA, with the prevailing share of arthroscopy of knee and shoulder. The market of arthroscopy of knee joints in the USA is estimated by the company to be more than USD 1 billion.
THE TEAM /
SVETLANA ZENKOVA,
CEO;
DMITRY KOTEGOV,
Vice President of Business Development;
ALEXANDER OZEKH,
Manager of the Medical Department;
ROY SHAFRIR,
Coordinator of Research and Development;
LEONID WAXMAN,
Medical Business Development Consultant.
JOINTECH™ SYNOVIAL SHUNT
IS A MINIMALLY INVASIVE THERAPY
FOR KNEE JOINTS
JOINTECH RUS LLC
CONTACTS /
Yekaterinburg
Dmitry Kotegov
+7 (963) 275 22 20
Kotegovd@yandex.ru
Russia, Sverdlovsk Region, Yekaterinburg,
ul. Lunacharskogo 31, of. 317

38
DEVELOPMENT AND RUSSIAN MARKET
RELEASE OF NEW MEDICAL LASER
SYSTEMS FOR SOFT AND HARD
TISSUE SURGERY
This modular laser system has several advantages in use:
- universal application and possible upgrades;
- compactness and portability;
- large, easy-to-use touchscreen;
- intuitive navigation and easy-to-use menu.
stLase surgical laser system with microprocessor control, touchscreen, and graphic operator interface, with power transmitted through fiber optic cable, contact, or contact-free methods.
ACHIEVED RESULTS /
The first lot (5 devices) of universal consoles withstLase modules have been producedfor trainingdoctors, demonstrations, and initial sales.
The stLase PE module is in development.
MARKET POTENTIAL /
The company works in close partnership with the international companies Dental Photonics and Laser Abrasive Technologies, as well as leading Russian institutes and organizations.
THE TEAM /
VYACHESLAV SELIVANOV,
CEO;
GRIGORY ALTSHULER,
Doctor of Engineering, Chief Scientific Advisor;
IGOR SHUGAYLOV,
Doctor of Medicine, Professor, Chief Medical Advisor.
PHOTONICS LLC
CONTACTS /
Moscow
Vyacheslav
Selivanov
+ 7 (495) 411 69 92
info@laserphotonics.ru
ul. Yakimanka B., 1
www.laserphotonics.ru

39
DEVELOPMENT AND
MANUFACTURING OF HI-TECH
SURGICAL TOOLS FOR BALLOON KYTHOPLASTY
The innovative medical product for balloon kythoplasty excels its analogues and has the market price 2–3 times lower than the competitors offer.
The balloon kythoplasty method served as a basis for the development of unique hi- tech medical tool used in the treatment of patients with spinal fractures.
ACHIEVED RESULTS /
A unique hi-tech medical tool that complies with the gold standards for a treatment of spinal compression fractures has been developed.
MARKET POTENTIAL /
A forecast of the global market of surgical tools for balloon kythoplasty is more than $ 950 mln in 2014. The potential customer base for a treatment is about 2 bln rubles.
THE TEAM /
ALEXANDER TOMA,
PhD in Medicine, neurosurgeon, CEO;
MEDIATOMA LLC
CONTACTS /
Saratov
Alexander
Toma
al_toma@mail.ru
8 S.M. Kirovaprospekt, 410600 Saratov,
Saratov region, Russia
www.mediatoma.ru

40
Multifunctionality is several tools built in one arm. Many degrees of freedom of movement. The relative cheapness of the robot without loss of functionality, while maintaining the advantages of robotic surgery.
MeMic system is a maneuverable medical robot with 18 degrees of freedom (DOF), integrated set of tools and is 12 times smaller than the surgeon’s hands.
ACHIEVED RESULTS /
The manufactured plastic laboratory prototype is tested for gripping movements of the operator’s hand and for their conversion into movements of the manipulator. The experiments with holding the needle and making sutures using two manipulators are under way.
MARKET POTENTIAL /
By 2016, the market of micro-invasive surgery will reach USD 35.5 bln. The surgeon armamentarium represents the largest segment of the market. Potential revenues could reach USD 651 mln + USD 65 mln would proceed from maintenance.
THE TEAM /
SVETLANA ZENKOVA,
CEO;
Dr. NIER SCHWALB,
Research, Scientific and Technical Consultant;
Dr. YOAV MINTZ,
Medical Director;
XENIA CHAGAN,
Business Consultant.
MEMIC - A ROBOTIC MANIPULATOR
FOR LAPAROSCOPY
MEMIK EVROPA LLC
CONTACTS /
Yekaterinburg
Svetlana Zenkova
svetik_z2001@mail.ru
Russia, Sverdlovsk Region, Ekaterinburg, ul. Lunacharskogo, 31, of. 304 B

41
UNIVERSAL BIODEGRADABLE
INTRAVASCULAR IMPLANTS (STENTS)
THAT RESTORE BLOOD CIRCULAT ION.
AN ALTERNAT IVE TO METAL ANALOGUES
Restore a blood circulation in vessels like
metallic stents, but in contrast to them
they dissolve completely after several months.
The vessel restores its normal function,
including motility. They prevent local
inflammation at the place of positioning and
restenosis.
Use of innovative multi-component polymer
compound as the material for stents
provides the following advantages:
- It simplifies the design of stents;
- It improves the mechanical properties as
Compared with existing stents.
ACHIEVED RESULTS /
A thermoplastic polymer compound has
Been developed.
Prototypes of biodegradable stents with
Specified mechanical parameters have been obtained.
A primary test for histocompatibility and
Biological safety has been performed.
Patent protection of the technology has
Been implemented.
MARKET POTENTIAL /
The global market of coronary stents in
2016 will reach $ 10.6 billion*.
Expected market annual growth rate - 8.3%
(BCC Research estimate).
THE TEAM /
MIKHAIL POPOV,
CEO.
OKSANA MANZENYUK,
PhD in Medical Sciences, Deputy CEO,
Project Manager.
NIKOLAI SOLOVYOV,
Doctor of Physical and Mathematical
Sciences,
Chief of Laboratory of Laser Discharges,
Instituteof Mechanics of the Russian
Academy of Sciences(IPMechRAS).
DMITRY KAPUSTIN,
PhD in Chemical Sciences, “Polymers
forBiology” laboratory, M.M. Shemyakin
and Yu.A. Ovchinnikov. Institute of
bioorganic chemistry of the Russian
Academy of Sciences (IBChRAS).
BIOSTEN
CONTACTS /
Moscow
Oksana Manzenyuk
+7 (495) 787 37 34
o.manzenyuk@stentex.ru m.popov@stentex.ru

42
The use of hLf APO with interferons and ribavirin reduces treatment duration on average from one year to 21 days and increases efficacy from 41% (Pegasys) to 80%.
Human lactoferrinapo (hLf APO) is lactoferrin with low iron saturation that interacts with hepatitis C virus; when the virus is titered in the blood, its amount decreases and the virus completely disappears (21 days).
ACHIEVED RESULTS /
The project is in the seed stage. The drug has been in research since 2000 and shows stable, positive results, which indicates that further studies are needed during drug approval.
MARKET POTENTIAL /
The hepatitis C treatment project is ambitious and revolutionary and has high potential for commercialization. The project’s research risks are low, as twelve years of studies show stable, positive results for treating hepatitis C.
THE TEAM /
SERGEY LESHKOV,
CEO;
NIKOLAI SHATUNOVSKIY,
Project Science Director;
EVGENY EFREMOV,
Project Scientific Consultant.
NEW DRUGS AND MEDICAL DEVICES
FOR TREATING PATIENTS WITH
VIRAL HEPATITIS C
INNOVATIVE MEDICINE LABORATORY CJSC
CONTACTS /
Moscow
Sergey Leshkov
sleshkov@list.ru
ul. Berzarina, 16
ANTI-VIRALDRUGS, VACCINESANDDIAGNOSTICS

ANTI-VIRAL DRUGS, VACCINESANDDIAGNOSTICS
43
DEVELOPMENT OF ORIGINAL DRUGS
FOR TREATING VIRAL INFECTIONS
AND METHODS FOR DIAGNOSING
VIRAL DISEASES
Triazavirin has the complex advantages:
- lack of side effects and activity against resistant forms of viruses;
- several dosage forms (including those under development);
- price.
An unique lab complex is being created for discovery research. Pilot projects are being organized to develop and scale up technologies for producing finished dosage forms of antiviral drugs.
ACHIEVED RESULTS /
The company has developed 15 original first-in-class active ingredients that are currently in virologic testing. Finished dosage forms have been developed for the first-in-class drug Triazavirin.
MARKET POTENTIAL /
By 2020, the company plans to hold up to 40% of the Russian antiviral drug market and enter the global market.
THE TEAM /
VALERY CHARUSHIN,
RAS Academician;
OLEG CHUPAKHIN,
RAS Academician;
VLADIMIR RUSINOV,
RAS Corresponding Member.
URAL CENTER FOR BIOPHARMACEUTICAL
TECHNOLOGIES LLC
CONTACTS /
Novouralsk
info@ucbt.uphc.ru
Russia,
Sverdlovsk Oblast,
Novouralsk,
ul. Podgornaya, 11

44
ANTI-VIRALDRUGS, VACCINES AND DIAGNOSTICS
A new class of molecules with activity against HBV characterized as an inhibitor of virus particle penetration into the cell. The mechanism of action ensures long- term eradication of HBV and prevents viral hepatitis D.
Myrcludex B is a chemically synthesized peptide chain of 47 amino acids. The mechanism of action lies in its ability to bind strongly to the NTCP receptor on the surface of a hepatocyte involved in HBV penetration into the cell.
ACHIEVED RESULTS /
A phase Ia clinical trial has demonstrated the drug’s safety and good tolerability. Phase Ib–IIa clinical trials are underway for Myrcludex B.
MARKET POTENTIAL /
Annually, around 50 million new cases of infection are diagnosed and roughly 2 million people die worldwide from liver infections: cirrhosis of the liver and liver cell carcinoma, as well as acute fulminant hepatitis.
THE TEAM /
OKSANA MARKOVA,
CEO;
PAVEL BOGOMOLOV,
PhD in Medicine, Medical Consultant;
ALEXANDER ALEXANDROV,
Development Advisor.
PROJECT PARTNERS:
Biotech company MYR, GmbH (Germany).
DEVELOPMENT AND COMMERCIALIZATION
OF A DRUG FOR TREATING CHRONIC
HEPATITIS B AND CHRONIC VIRAL
HEPATITIS D
HEPATERA LLC
CONTACTS /
Moscow
Oksana
Markova
+7 (495) 411 69 92
hepatera@gmail.com
ul. BolshayaYakimanka, 1
www.hepatera.ru

45
ANTI-VIRAL DRUGS, VACCINES AND DIAGNOSTICS
The new drug has a novel mechanism of action, which opens up the important market sector of antiretroviral therapy. It has significantly greater efficacy than competing developments. In addition, the target matrix protein p17 of the human immunodeficiency virus (HIV) is one of the most conservative in the HIV genome, which should reduce the risk of drug resistance.
Small molecules “designed” using computer modeling inhibit the activity of HIV matrix protein p17 and suppress virus replication in the cell. The new drugs have fundamentally novel mechanisms of action.
ACHIEVED RESULTS /
Preclinical studies have begun. HIV matrix protein p17 inhibitors have high activity and low toxicity. Patent applications have been submitted in Russia, Germany, USA, and Japan; 7 articles have been published in foreign scientific journals.
MARKET POTENTIAL /
The fight against HIV is one of the top priorities of modern healthcare. The global sales market for antiretrovirals is more than 20 billion dollars; 3–5% of these sales are in Russia.
THE TEAM /
PETER FEDICHEV,
CEO, CSO, head of R&D;
MAXIM KHOLIN,
Deputy of CEO;
ALEXANDER KADUSHKIN,
Head of chemistry department, medical chemistry;
TIMOFEY PYRKOV,
Chief research worker, head of drug development, including pre-clinical and clinical trials;
Evgeny Getmantsev,
Head of development and usage of IT in drug research and analysis of experimental data.
HIV MATRIX PROTEIN MA/P17
INHIBITORS FOR TREATING HIV/AIDS
QUANTUM PHARMACEUTICALS LLC
CONTACTS /
Moscow
Maxim Kholin
+7 (499) 156 15 61
+7 (499) 150 83 32
maxim.kholin@
q-pharm.com
www.q-pharm.com

47
DEVELOPMENT OF A NEW
GENERATION OF ANTIFUNGAL
COMPOUNDS USING IN SILICO
AND IN VITRO SCREENING
The new effective drug is the subject of interest of all the players, as it allows getting a significant share of the market in monetary terms due to the exclusive rights for its production.
Construction of new synthetic CYP51 inhibitors.
ACHIEVED RESULTS /
The analysis of chemical space is carried out. Selection of compounds that bind to target proteins of pathogens and do not interact with the xenobiotic metabolism system of the human body.
MARKET POTENTIAL /
Antifungal agents belong to the group with a high steady demand. The average yield from their sale is about 50-55%. The specific share of the total world market in USA is 35%, in Europe - 25%, in Japan -30%.
THE TEAM /
ALEXEY KLYUCHENOVICH,
CEO;
DMITRY MUKHA,
Deputy CEO;
ALEXEY YANTSEVICH,
Head of the Operations in the Field of Analytical
Methods and Chemical Synthesis;
ANDREY GILEP,
Head of Operations in the Field of Molecular Cloning;
SERGEY USANOV,
Project Coordinator.
CONTACTS /
Moscow
Alexey
Klyuchenovich
info@target-medicals.com; dmitry.mukha@iboch.
bas-net.by
Maliy Sukharevsky per., 9,
build. 1, of. 36
www.target-medicals.com
TARGET MEDICALS LTD.
MOLECULAR MODELING TOOLS, MOLECULAR INTERACTIONMODELS AND TOOLS

48
The new drug can solve key problems in treating Parkinson’s Disease: it increases the efficacy and safety of palliative treatment, slows disease progression, and eliminates non-motor symptoms.
The drug has an innovative mechanism of anti-Parkinson’s action; it has advantages over known classes of anti-Parkinson’s drugs and is potentially competitive on the global market.
ACHIEVED RESULTS /
Dozens of biologically active compounds have been synthesized and studied. These compounds have been compared for efficacy of anti-Parkinson’s activity and safety of use. Safety and efficacy indices have been studied.
MARKET POTENTIAL /
For the Russian market, where imported anti-Parkinson’s drugs dominate (over 85%), this is the first original drug in the segment that can replace imports.
THE TEAM /
VENIAMIN KHAZANOV,
Doctor of Medicine, Professor, Project Manager;
NARIMAN SALAKHUTDINOV,
Doctor of Chemistry;
NATALYA BELSKAYA,
Doctor of Medicine, Deputy CEO.
INNOVATIVE DRUG FOR
TREATING PARKINSON’S DISEASE
RIONIS LLC
CONTACTS /
Tomsk
Veniamin
Khazanov
antiparkinson@mail.ru
Russia,
Tomsk Oblast,
Tomsk, ul. Elizarovykh,
D. 79/4
Normal brain
Brain with
Parkinson’s Disease
NEUROLOGICAL DRUGS & DIAGNOSTICS

49
Odelepran may have a more favorable efficacy-to-safety ratio compared to naltrexone.
Odelepran is a new opioid receptor antagonist that demonstrates high in vitroaffinity and antagonism toward all 3 types of human opioid receptors.
ACHIEVED RESULTS /
A series of preclinical studies have been completed, as well as phase I and II clinical trials of the tablet dosage form of Odelepran in patients with alcohol dependence.
MARKET POTENTIAL /
The market will grow as new drugs with proven efficacy appear. Naltrexone is the only effective drug for treating narcotic dependence available in Russia.
ODELEPRAN: NEW OPIOID
RECEPTOR ANTAGONIST
R-OPRA LLC
CONTACTS /
Moscow
Sergey Grishin
+7 (963) 683 05 71
sa.grishin@rpharm.ru
ul. Berzarina, 19,
korp. 1
NEUROLOGICAL DRUGS & DIAGNOSTICS

50
Applying of a new type of fluorescent biocompatible markers on the basis of nanodiamond and nanographite. The expected parameters will drastically exceed those of domestic and foreign competitors.
An alternative approach to the development of luminescent nanodiamonds to be applied as biomarkers is based on chemical sedimentation of diamond from the gaseous phase (CVD method).
ACHIEVED RESULTS /
The work is carried out at the RAS Institute of General Physics laboratories, where experimantal plants for CVD diamond growth have been developed.
MARKET POTENTIAL /
The global biomarker market will grow from USD 5 bln (2009) to USD 20 bln (2014), oncobiomarkers– from USD 4.1 bln (2009) to USD 9.5 bln (2014). The applications in cardio and central nervous system treatment in 2007 totaled 23% of the biomarker market.
THE TEAM /
IGOR VLASOV,
RusNano scientific expert, CEO;
VIKTOR RALCHENKO,
PhD in Physics and Mathematics, CSO;
VIKTOR LOSHCHENOV,
Doctor of Physics and Mathematics, scientific expert;
VITALY KONOV,
Doctor of Physics and Mathematics, Prof., RAS corresponding member, scientific expert;
TATIANA EGOROVA,
investment analyst at NC «TECHNOSPARK»,
development manager.
BIOMEDICAL MARKERS ON THE BASIS
OF HIGH-STABLE LUMINESCENT
CARBON NANOMATERIALS
ADAMARK LLC
CONTACTS /
Troitsk
Igor Vlasov
+7 (916) 601 87 36
mp@ttorr.ru
1 Sirenevy bulvar,
142190 Troitsk,
Moscow region,
Russia
TRANSLATIONAL (PERSONALISED) MEDICINE BIOMARKERS

51
PETAR: A NEW METHOD FOR PERSONALIZED TREATMENT OF CANCER
AND AUTOIMMUNE DISEASES
A personalized method of treating tumors and autoimmune diseases can reduce costs for purchasing expensive drugs for patients who do not respond to the standard treatment.
Determination of an individual set of targets for treatment based on a patient’s biological tissues; creation of patient- specific protein molecules based on the selected targets; administration of individualized medicine to the patient.
ACHIEVED RESULTS /
Sets (cassettes) of therapeutic antibodies are developed against individual tumor antigens, as well as cassettes of immunotoxins for destroying pathological B cells in autoimmune diseases.
MARKET POTENTIAL /
Individual targeted drugs based on immunotoxins against specific B cell clones, which develop autoantibodies against neuroantigens, as well as antibodies against cancer antigens for treating multiple sclerosis and several forms of cancer.
CONTACTS /
Moscow
Alexander
Gabibov
ivolodin74@mail.ru
ul. Miklukho-Maklaya,
16/10, korp. 12
PERSONALIZED TECHNOLOGIES DEVELOPMENT
CENTER LLC (PETAR CENTER LLC)
TRANSLATIONAL (PERSONALISED) MEDICINE, BIOMARKERS
Level of Health
validation of treatment method
treatment
Cost of treatment
Blockbuster treatment
PeTAR

CANCER DRUGS & DIAGNOSTICS
53
INNOVATIVE BIFUNCTIONAL
TARGET-SPECIFIC SMALL MOLECULE
ANTI-CANCER DRUGS
Selectivity, wide spectrum of effects, high efficacy due to bifunctional action, reduced risk of drug resistance.
The new drugs cause programmed cell death of cancer cells by simultaneously inhibiting functionally distinct factors that regulate the growth and death of cancer cells.
ACHIEVED RESULTS /
A candidate drug has been selected.
MARKET POTENTIAL /
The global sales volume of anti-cancer drugs will reach 72 billion dollars in 2016.
THE TEAM /
VLADIMIR KUCHEROV,
Director;
GALINA SELIVANOVA;
VLADIMIR POROYKOV;
ALEXANDER KEL.
CONTACTS /
Moscow
Vladimir Kucherov
contact@a-lab.com.ru
A-LABORATORY LLC

54
Usage of Medicinal Nanoengineering™ platform. High efficacy of medicines in combination with reduced side effects and toxicity.
Accurins™ is accumulated in the target tissue and locally releases the active substance there. The result is the maximum therapeutic efficacy of the drug against the reduced toxicity related to its systemic administration.
ACHIEVED RESULTS /
The flagship product of Accurins™ class Bind-014 is currently under development in early Phase II clinical trials in patients with cancer in the United States and Russia.
MARKET POTENTIAL /
Accurins™ technology can be used both for existing drugs, and for compounds that are under development, which allows producing the best-in-class drugs.
THE TEAM /
ELMIRA SAFAROVA,
PhD., CEO;
JEFF HRKACH,
PhD., Scientific Consultant;
STEPHEN ZALE,
PhD., Scientific Consultant;
NATALIA SAMSONENKO,
MBA, Financial Director;
ARKADY ZINCHENKO,
PhD., Head of the Preparation of Dosage Forms Department;
DMITRY ANDREEV,
PhD., Head of Analytic Department.
DEVELOPMENT OF MEDICINES BASED ON THE TARGETED POLYMERIC
NANOPARTICLES
BIND (RUS) LLC
CONTACTS /
Moscow
Elmira Safarova
ElmiraSafarova@
bindtherapeutics.com
117246, Russia, Moscow, Nauchnyiproezd, 20, bldg. 2 www. bindtherapeutics.com

55
Versatility of action, low toxicity, high specificity. Inhibition of telomerase:
- Reduces the potential of malignant cells division;
- Destroys the primary tumor and metastases;
- Decreases the ability of the primary tumors to metastasize.
The drug developed under the project shall have substantially lower toxicity (analogues of this class of compounds, according to published data, do not have high toxicity) and greater selectivity for tumor cells.
ACHIEVED RESULTS /
Testing of compounds panel (search for more active compounds with improved physico-chemical properties). Conducting in vivo studies - evidence of the antitumor activity of compounds affecting the assembly of the enzyme.
MARKET POTENTIAL /
The world market of anticancer drugs is USD 80 billion. The developed drugs will have a significantly lower cost compared to the analogues with the effect not inferior to them.
THE TEAM /
MARIA ZVEREVA,
Project Manager;
ALEXANDER MAZHUGA,
CEO;
ALEXANDER KABANOV,
Scientific Consultant;
OLGA DONTSOVA,
Scientific Consultant.
SYNTHESIS AND PRE-CLINICAL TRIALS
OF A NEW TYPE OF ANTICANCER DRUGS, TELOMERASE INHIBITORS
ONCOBIOTECH LLC
CONTACTS /
Moscow
Alexander Mazhuga
maguga@mail.ru
119311, Moscow,
pr-t Vernadskogo, 15, apt. 316

56
DEVELOPMENT AND COMMERCIALIZATION OF VACCINES BASED ON NANOPARTICLES
Synthetic vaccines have:
- Higher efficacy
- Enhanced safety profile through targeted delivery
- Short production cycle due to the synthetic components
- A lower cost of manufacturing process.
Synthetic vaccines produced by Selecta based on tSVP™ nanoparticles are designed to meet the most current knowledge about immune system acting to produce an optimal immune response.
ACHIEVED RESULTS /
1. The experimental results have confirmed the concept of vaccine acting against cancer.
2. Phase I clinical trials of anti-nicotine vaccine has been completed.
MARKET POTENTIAL /
1. The market of immuno-oncology drugs will reach USD 1.5 billion by 2018
2. The market of agents for smoking cessation aid will reach USD 4.5 billion by 2018
THE TEAM /
WERNER CAUTREELS,
CEO;
DMITRY OVCHINNIKOV,
Deputy CEO;
NATALIA BASTRIKOVA,
Director of Corporate Development and Clinical Research.
CONTACTS /
Moscow
Natalia Bastrikova
nbastrikova@
selectarus.com
141400, Russia, Moscow
Region, Khimki,
ul. Rabochaya, 2 a, build 1
www.selectabio.com
SELECTA (RUS) LLC

57
A unique mechanism of TAV08 action on the key stages of pathogenesis by restoring the balance of different types of cells, but not by eliminating the consequences of autoimmune disease pathogenesis.
An unique Russian drug for a treatment of B-cell chronic lymphocytic leukemia and autoimmune diseases.
ACHIEVED RESULTS /
The first phase of clinical trials for TAB08 has been completed.
Since the launch of the project, 10 international patents (PCT, US), including the developed in-vitrotechnology resTore, have been received.
All intellectual property is owned by TheraMAB LLC.
MARKET POTENTIAL /
Involving an additional round of funding will allow completing Phase 3 clinical trials for TAV08 in the Russian Federation or other countries and launch TAV08 in the market.
At the moment, there is an evidence of a powerful therapeutic potential of TAV08.
THE TEAM /
DMITRY TYRSIN,
PhD University of Wrzburg, CEO.
ALEXEY MATSKEVICH,
PhD in Biological Sciences, Research Director.
YURI FEDOTOV,
Pre-clinical and Clinical Research Director.
MIKHAIL PANTELEEV,
PhD in Biological Sciences, Head of Science
Department.
DANIIL NEMENOV, Clinical Research Manager.
MEDICINE FOR A TREATMENT
OF AUTOIMMUNE DISEASES AND CHRONIC LYMPHOCYTIC LEUKEMIA HAVING
A POWERFUL THERAPEUTIC POTENTIAL
THERAMAB
CONTACTS /
Moscow
Dmitry Tyrsin
+7 (495) 974-74-01
tyrsin@bioprocess.ru
www.theramab.ru

58
The developed diagnostic system will allow:
- Excluding the costs for the therapy known to be ineffective,
- Avoiding selection of drugs by trial and error method,
- Increasing effectiveness of oncology patients’ treatment.
System diagnostics and personalized selection of the optimal cancer treatment will allow to detect numerous defects in a tumor, and at the same time to analyze them using proprietary technology in the automatic mode.
ACHIEVED RESULTS /
Diagnostic panel and analytical software have been designed, tested and optimized for inclusion into the Silver, Gold and Platinum versions. In collaboration with N. N. Blokhin Russian Cancer Research Center, a range of evidences of the system effectiveness has been obtained.
MARKET POTENTIAL /
The diagnostic system will be available in three versions that will differ in cost and type of diagnostics, a doctor and a patient will be able to choose the most appropriate one.
THE TEAM /
TATIANA NIKOLSKAYA,
CEO;
SERGEY TYULYANDIN,
Head of the Clinical Part of the Project;
ALEXANDER KHVAT,
Head of Medical and Chemical Part of the Project;
MIKHAIL FEDYANIN,
Associate Contractor in the Clinical Part of the Project.
PROJECT PARTNERS:
N. N. Blokhin Russian Cancer Research Center.
IMPLEMENTATION OF TECHNOLOGY
FOR EARLY DIAGNOSIS, SELECTION
OF INDIVIDUAL DRUG COMBINATIONS
AND PERSONALIZED MEDICINE
IN ONCOLOGY IN RUSSIA
RUSGENDIAGNOSTICS LLC
CONTACTS /
Khimki
Tatiana Nikolskaya
tnikolsk@gmail.com 141400, Russia,
Moscow Region, Khimki,
ul. Rabochaya, 2a,
bldg. 1

59
STUDY OF RPT835: A SMALL MOLECULE
INHIBITOR OF FIBROBLAST GROWTH
FACTOR RECEPTOR 2 IN THE TREATMENT OF MALIGNANT TUMORS
The new drug blocks both “hot spots” (pharmacophore centers) and atypical bonds for blocking inside the receptor (know-how). The chemical structure is unique. It interacts specifically with one receptor and is classified as a targeted drug. It is less toxic; dose escalation may not be required due to selective action solely on a section of the FGFR2.
In contrast with other targeted drugs on the market or in development, RPT835 selectively blocks specific sections of fibroblast growth factor receptor 2 (FGFR2) without affecting other receptors, which significantly suppresses the growth of refractory malignant tumors while simultaneously reducing side effects. Cutting-edge biochemical technology is used to produce the drug.
ACHIEVED RESULTS /
- the molecule and modifications have been developed;
- de novo studies have confirmed the molecule’s action on receptor active centers;
- by October 2012, the amount of RPT835 needed for the first phase of preclinical efficacy studies (in vitro studies) had been chemically synthesized, and the physical and chemical properties of the active ingredient had been described;
- in October 2012, in vitro studies demonstrated the drug’s effect on phosphorylation of fibroblast growth factor receptor 2, i.e., the main mechanism that activates the receptor;
- in March 2013, in vivo studies were completed on RPT835’s effect on angiogenesis in mice;
- the drug is currently in the preclinical study stage.
THE TEAM /
TAMARA TIMOFEEVA,
CEO;
SERGEY TULYANDIN,
Chief scientific officer;
ILYA TIMOFEEV,
Scientific consultant;
MIKHAIL BIAKHOV,
Project coordinator;
CONTACTS /
St. Petersburg
Ilya Timofeev
office@ruspharm.com
190103, St. Petersburg, ul.11-ya Krasnoarmeyskaya, dom 16, liter A,
pomeshchenie 5-N
+7 (812) 937 29 65
www.ruspharm.com
RUSSIAN PHARMACEUTICAL TECHNOLOGIES LLC

60
High bioavailability of DIM provides effective concentrations of the active substance in the lesions. High selectivity of the active substance relative to the transformed cells. No severe toxicity and side effects.
The first low-toxic anticancer drug with selective inhibitory activity against tumor stem cells, which are the source of tumor recurrence and metastasis.
ACHIEVED RESULTS /
Preclinical studies have been completed, pharmacokinetics and pharmacodynamics of the drug have been studied. Preclinical studies of specific pharmacological activity in vitro have been completed as well as the effectiveness of the drug in vivo.
MARKET POTENTIAL /
The market volume of drugs used in Russian Federation for the treatment of oncology diseases of reproductive system is USD 200 million Forecast of the sector development up to 2015 is minimum USD 1 billion.
THE TEAM /
VSEVOLOD KISELEV,
Research Manager;
KUSHLINSKY NIKOLAY,
FAZLUL H. SARKAR,
International Consultants;
DMITRY SIDORIN,
Engineer, Production of Drugs Consultant; GEORGIY FRANK,
Study Doctor in Clinical Trials;
RUSTEM KHASANOV,
Study Doctor.
DEVELOPMENT OF A NEW DRUG
FOR TREATMENT OF THE HUMAN
REPRODUCTIVE SYSTEM CANCERS
ANO NATIONAL INSTITUTE OF INNOVATION
CONTACTS /
Moscow
Vsevolod Kiselev
+7 (495) 989 45 93
info@anonii.ru
123100, Russia,
Moscow,
Presnenskaya nab., 12
www.anonii.ru

61
The key differences of the product from existing solutions and new products:
- The possibility of mass production;
- High efficiency for many types of solid malignant tumors;
- The possibility of tumor development prevention.
The proposed product is developed as a non-individualized vaccine that is suitable for treatment of various forms of solid tumors.
ACHIEVED RESULTS /
Technical specifications of the product, achieved at this stage: the efficacy on animal models is more than 60%.
Completion of PRAV vaccine prototype is planned to achieve the treatment rates efficacy in humans of up to 70%.
MARKET POTENTIAL /
Mass production of PRAV vaccine will lead to treatment accessibility for many types of solid tumors. PRAV vaccine which is under development will have global competitiveness.
THE TEAM /
OLEG KRYLOV,
CEO;
RUSTEM AMIROV,
Deputy CEO;
ALEXANDER POLETAEV,
Research Project Manager;
SHAMIL GANTZ,
Chief Consultant in Oncology;
ANDRES BREDBERG,
Consultant in Molecular Studies.
PROJECT PARTNERS:
CJSC «Managing Company «Savings and Investments».
DEVELOPMENT OF A NON-INDIVIDUALIZED METHOD OF SPECIFIC IMMUNOTHERAPY
OF MALIGNANT SOLID TUMORS
A-VAK LLC
CONTACTS /
Moscow
Oleg Krylov
krylov@immunculus.ru
ul. Rustaveli, 3,
block 7, apt. 9

62
INNOVATIVE LUMINESCENT
NANOMATERIALS AND TECHNOLOGIES
FOR THEIR APPLICATION IN BIOMEDICINE
Luminescent nanocrystals with unique ability to convert the driving infrared radiation into luminescence in the visible and infrared ranges: solution of the tissue autofluorescence problem, clear visualization of the labeled lesions boundaries.
Pathological tissues are labeled with the targeted fluorescent molecular probes.
ACHIEVED RESULTS /
Technical risks of the project can be deemed minimal. The synthesis of anti- Stokes nanophosphors, solegated by erbium and thulium ions, was developed. The stability of surface-modified NAPhs has been confirmed.
MARKET POTENTIAL /
The proposed technology is competitive on the domestic and global markets and can have a positive impact on import substitution.
THE TEAM /
VLADIMIR SOKOVIKOV,
CEO;
ANDREY ZVYAGIN,
Research Manager;
ANDREY NECHAEV,
Expert in Chemical Synthesis;
ANNA GULLER,
Expert in Biomedical Research;
PROJECT PARTNERS:
STC «Amplitude» LLC.
CONTACTS /
Moscow
Andrey
Zvyagin
mithrelfluoro@gmail.com
Russia, Moscow,
ul. Lyapidevskogo 10,
apt. 41
MITHREL-LUMITEC LLC

63
Previously, this molecule has never been used as a target in the treatment of renal cell carcinoma. New drug is capable of inhibiting tumor growth by more than 90%, has low immunogenicity and toxicity due to the high levels of human protein (93%).
OM-RCA-01 is an antiangiogenic drug on the basis of monoclonal antibodies to the fibroblast growth factor receptor for cancer treatment.
ACHIEVED RESULTS /
Antibody humanization has been performed;producer has been developed.
Efficacy in vitro and in vivo has been confirmed.
Preclinical safety studies were initiated.
Patents have been received in the Russian Federation and USA.
6 scientific articles, including articles in the International Journal of Cancer, have been published.
MARKET POTENTIAL /
Drugs based on monoclonal antibodies to fibroblast growth factor receptor are practically unavailable on the market.
The market of drugs for the treatment of renal cell carcinoma (United States, Japan and the EU) is about $ 950 million. Russian market capacity is about 5 billion rubles.
THE TEAM /
ELINA ZAVELEVA,
PhD (Biology), CEO.
ILYA TIMOFEEV,
Scientific Consultant, author of development.
ANTON TIKHONOV,
Project Manager
COMPANY PARTNERS:
Research and Development – PX’Therapeutics,
Goodwin Biotechnology, Genetika, EUGENEXBiotechnologies, Charles River.
Companymanagement – Maxwell Biotech Group.
NEW LOW-TOXICITY DRUG FOR KIDNEY CANCER TREATMENT
ONCOMAX
CONTACTS /
Moscow
Elina Zaveleva
+7 (495) 411-69-92/93
info@oncomax.ru
www.oncomax.ru

64
THE PORTFOLIO OF ANTICANCER DRUGS
UNDER DEVELOPMENT BASED ON NOVEL SCIENTIFIC CONCEPT
OF «ANTI-TISSUE CHEMICAL SURGERY»
The new drug may solve the problem of insufficient selectivity of the existing anticancer drugs and prevent development of drug-resistant and metastatic tumor types, reduce the severity of chemotherapy side effects.
The new approach based on the principle of specificity to the body tissues, a kind of ‘pharmacological surgery,’ opens the opportunities of creating a principally novel class of anti-tumor agents.
ACHIEVED RESULTS /
Perspective hit compounds have been obtained; they are currently being characterized and optimized, most likely modes of action and efficacy in animal models are being investigated.
MARKET POTENTIAL /
The cancer types, which the project aims to, make up above 40% of all registered oncology diseases. The global market of anticancer drugs is currently approximating USD 100 bln.
THE TEAM /
ANDREY GUDKOV,
Doctor of Biology, Prof., scientific initiator of theproject;
OLGA CHERNOVA,
PhD in Biology, head of R&D;
ALEXANDER POLINSKY,
PhD in Chemistry, president of the company;
ANDREY LEONOV,
PhD in Chemistry, CEO, OncoTartis LLC
PROJECT PARTNERS:
Roswell Park Cancer Institute (RPCI) (Buffalo, NewYork, USA).
ONCOTARTIS LLC
CONTACTS /
Moscow
Andrey Leonov
+7 (495) 974 74 01
(ext. 245)
leonov@bioprocess. ru Bldg. 2, 6 Stolovypereulok,
121069 Moscow,
Russia

65
The efficacy and safety of anticancer drugs with a new mechanism of action has been proved by direct measurements of the enzyme.
All drugs developed in the framework of the project act against the same targeted molecule, glycolytic enzyme of 6-phosphofructo-2-kinase/fructose-2,6 biophosphatase-3 (PFKFB3). Current enzyme is overexpressed in the different types of tumor lines, thus, it provides broad spectrum of drugs action.
ACHIEVED RESULTS /
Several classes of compounds with anticancer activity confirmed in-vitro and in-vivo were obtained. The developed analogues show the activity and the therapeutic window on the same level or better than the molecules developed by competitors.
MARKET POTENTIAL /
Development of an effective and safe anticancer drug with the new mechanism of action. The colon and pancreatic cancer morbidity is growing, therefore, providing high market potential for the drug under development.
THE TEAM /
PETR FEDICHEV,
CEO;
TATIANA ZHIDKOVA,
Research Assistant;
TIMOFEY PYRKOV,
Research Assistant.
DEVELOPMENT OF GLYCOLYSIS
REGULATORS AS A NEW CLASS
OF MEDICINES
QUANTUM AGE LLC
CONTACTS /
Moscow
Petr Fedichev
glikoliz3@gmail.com
Russia, Moscow,
ul. Profsouznaya, 26/44,
of. II, r. 1

66
DRUGS FOR TREATING ONCOLOGICAL AND NEUROLOGICAL DISEASES BASED
ON NANOSCALE DELIVERY SYSTEM
TECHNOLOGIES (NANOMEDICINE)
The proposed delivery systems allow drugs to efficiently penetrate into the nidus via directed transport. Delivery systems provide a 1.5–3-fold increasein drug bioavailability, efficacy, and safety.
The key element is a drug delivery system using lactic and glycolic acid copolymers (50–350 nm nanoparticles) and a medicine delivery system using albumin particles (100–350 nm nanoparticles).
ACHIEVED RESULTS /
The developed drugs are in the early and late stages of preclinical studies.
MARKET POTENTIAL /
In 2009 the global market of drug delivery systems was worth over 100 billion dollars, and it is forecasted to grow to 200 to 700 billion dollars by 2015.
The market for neurological, oncological, and genetic drugs comprises over 55% of the entire pharmaceutical market.
THE TEAM /
YASIR HAMDY,
CEO.
PROJECT PARTNERS:
Frankfurt University;
King’s College London;
Geneva Foundation for Medical Education and Research,
WHO Collaborating Centre;
CNRS Research Institute of Biotechnology, France;
I.M. Sechenov First Moscow State Medical University of the Russian Federation Ministry ofHealth and Social Development.
LEKSYSTEMS LLC
CONTACTS /
Moscow
YasirHamdy
y_hamdy@mail.ru,
denistom@mail.ru;
ul. Skakovaya, 32, build. 2

67
TECHNOLOGY FOR PREDICTING
RECURRENCES AND CHEMOTHERAPY
SENSITIVITY IN PATIENTS WITH BREAST
CANCER BASED ON GENE EXPRESSION ANALYSIS
A unique gene pattern in a panel and a unique algorithm to calculate recurrence risk, accessible to consumers in Russia, relatively low cost. There are no Russian analogs.
The new technology creates a system to determine the gene expression profile for malignant tumors to identify groups of patients with stage I–IIa breast cancer with high and low risk of distant metastasis.
ACHIEVEDRESULTS /
A bank has been created with 370 paraffin wax-embedded tissue samples. A method has been developed for obtaining results from the morphological description stage before results of gene expression are obtained.
MARKET POTENTIAL /
This innovation has the potential to achieve structural shifts in the industry or significant changes in technologies used and/or process costs.
THE TEAM /
VLADIMIR BOZHENKO,
Doctor of Medicine, Professor, PhD in Biology, Project ResearchAdviser;
OLEG BLIZNYUKOV,
Doctor of Medicine, Pathomorphologist, Research Consultant;
ELENA KUDINOVA,
PhDin Medicine, Clinical Diagnosis Laboratory Doctor, Research Consultant; SERGEY KARBAINOV,
CONTACTS /
Moscow
Vladimir Bozhenko
+7 (495) 778 75 88
bbii@mail.ru, polidar@ yahoo.com
Russia, Moscow,
ul. SalyamaAdilya, 9, off. 1, room 2
GAMMA GLOBAL LLC

68
The product’s key distinction is the ability to simultaneously increase reliability and decrease the overall cost of analysis of oncomutations. The developers have obtained experimental proof of concept for a technology to detect one mutant DNA molecule in over 100,000 molecules without mutations.
The new approach combines specialized DNA sample preparation and a unique bioinformatics method for processing sequencing data, which eliminates internal technical error of the methods used.
RESULTSACHIEVED /
Test systems for high-precision analysis of oncomutations:
2013: CancerSnap-7 test system prototype produced
2014: CancerSnap-50 test system in development
MARKETPOTENTIAL /
The company plans to release the product to the clinical market in 2016.
THE TEAM /
ANDREY ZARETSKY,
Test Systems Design and Validation Manager;
DMITRY SHAGIN,
Research and Development Manager;
IVAN VOLCHENKOV,
Bioinformatician/Programmer;
TIMOFEY PANFILOV,
CEO.
MENTORS /
SERGEY ANATOLYEVICH LUKYANOV, Russian Academy of Sciences Academician;
NIKOLAY VLADIMIROVICH ZHUKOV, Clinical Oncology Director at the Federal Scientific Clinical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev.
THE TECHNOLOGY OF DIFFERENTIAL
ANALYSIS OF ONCOMUTATIONS IN COMPLEX DNA SAMPLES (DAOCS) FOR EARLY
NONINVASIVE GENETIC TESTING
FOR CANCER
NOVEL MOLECULAR TECHNOLOGIES LLC (NOMOTECH)
CONTACTS /
Moscow
Timofey Panfilov
ul. Miklukho-Maklaya,
d. 16/10, korp. 15
+7 (495) 988 40 83
www.nomotech.ru
daoss@nomotech.ru

69
The drug acts directly on several targets in the tumor cell, reducing its ability to produce drug resistance and increasing the efficiency of tumor growth suppression. Due to the lack of genotoxicity, safe long-term use is possible.
A new class of drugs (first-in-class), fundamentally different from the existing drugs developed by other international companies by the mechanism of action and efficacy. Curaxins do not cause DNA damage, as opposed to conventional chemotherapeutic agents.
ACHIEVED RESULTS /
- CBL0102
Phase I clinical trials (RF) have been completed. PhaseI/II clinical trials in combination with erlotinib (USA) were launched.
- CBL0137
Equator of Phase I clinical trials (RF).
Start of Phase I clinical trials (USA).
Date of drug release is 2016 in the
Russian Federation, 2018 in the USA.
Worldwide patents are owned by Incuron LLC.
10 invention patents, 26 international applications that during 2013-2014 will become national patents covering the world’s pharmaceutical market.
MARKET POTENTIAL /
Oncological diseases hold the leading positions in the structure of morbidity and mortality. Segment of targeted anticancer drugs is 65-70% of the total market.
THE TEAM /
ANDREY LEONOV,
PhD in Chemical Sciences,
CEO.
ROMAN IVANOV,
PhD in Chemical Sciences.
RAMIZ SALIMOV,
Doctor of Biological Sciences.
POLINA SHPIGOTSKAYA,
PhD in MedicalScience.
ANDREY GUDKOV,
Doctor of Biological Sciences,
Roswell Park Cancer Institute.
ANDREYPURMAL,
PhD in Chemical Sciences,
Cleveland Biolabs.
NOVEL CANCER DRUG THAT
DOES NOT CAUSE NORMAL DNA DAMAGE
INCURON
CONTACTS /
Moscow
Andrey Leonov
+7 (495) 974-74-01
info@incuron.ru
www.incuron.ru
www.incuron.com

70
DEVELOPMENT OF A DEVICE FOR
HIGH-VALUE INSTANT DIAGNOSIS OF
PROSTATE CANCER BASED ON THE ANALYSIS OF PROSTATIC SECRETIONS AND EJACULATE
The developed product will be in demand on the market at the time of commercialization due to the considerably higher sensitivity and lower price. There are no Russian and foreign analogues of this test.
The levels of certain biomarkers of non-protein origin are measured in the prostatic secretions and/or ejaculate. The sample is evaluated using colorimetric, enzymatic and electrochemical methods.
ACHIEVED RESULTS /
An application is filed for obtaining an international patent for the product. Development and creation of a portable diagnostic device. Clinical trials of a portable diagnostic device.
MARKET POTENTIAL /
The developed test can replace the PSA test and drive the latter out of the market of prostate cancer diagnostics both in Russia and abroad.
THE TEAM /
MAXIM ROSSMANN,
PhD, Project Director;
DMITRY SOLOVYOV,
PhD in Chem. Sc., Research Project Manager
IRINA SOLMATOVA-SOLOVYEVA,
CEO;
PAVEL SHASHKOV,
PhD in Phys-Math. Sc., Commercial Director;
ISTVAN BOROS,
PhD, Intellectual Property Development;
SERGEY USOV,
CONTACTS /
St. Petersburg
Irina
Solmatova-Solovyeva
+7 (812) 635 75 44
office@camonx.com
Russia, 191014, St.Petersburg,ul. Vosstania 30/7, build.A, of. 11-Н
www.camonx.com
ONCOMETRIX LLC

71
IMMUNOTHERAPY OF B CELL
MALIGNANT DISEASES
Generium’s bispecific molecule demonstrates higher killing of malignant cells and improved drug tolerability properties.
The molecule recognizes a B cell marker that is found in a wide range of hematologic malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and various types of non-Hodgkin lymphomas.
ACHIEVED RESULTS /
The project will involve creating a bispecific antibody (BsAB) aimed at engaging cytotoxic effector cells of the human immune system against lymphoma B cells.
MARKET POTENTIAL /
In comparison with other BsAB designs, Generium’s bispecific molecule demonstrates higher killing of malignant cells and improved drug tolerability properties.
THE TEAM /
SERGEY RUCHKO,
CEO;
DANIIL TALYANSKY,
Chief Business Officer;
ANDREY PETROV,
Chief Science Officer;
MAXIM LYKOV,
COO;
IGOR GOVOROV,
CTO.
CONTACTS /
Moscow
Daniil Talyansky
+7 (495) 989 46 75
tds@ibcgenerium.ru
ul. Testovskaya, 10
GENERIUM INTERNATIONAL
BIOTECHNOLOGY CENTER LLC

72
1. sensitivity and specificity of 95–98% (better than any other cancer diagnosis methods)
2. detects all types of cancer
3. effective even at early stages of disease
4. requires only 0.2 ml of blood plasma (no biopsy needed)
5. quick (24 hours), inexpensive (cost price approximately $250)
The test is based on analyzing methylation of free circulating DNA. A unique DNA amplification method allows for analysis of methylation of the entire genome using 0.2 ng of DNA. A method has been developed to select biomarkers for the entire genome, which achieves sensitivity and specificity of 95–98%.
ACHIEVED RESULTS /
A DNA amplification technique has been developed, a platform has been created to search for biomarkers, and candidate biomarkers have been selected. Preliminary studies of M-TEST: 1 error in 33 samples, test duration 24 hours, test cost price approximately $250.
MARKET POTENTIAL /
M-TEST can be used for cancer screening (universal test for all types of cancer), for confirming diagnosis, and for monitoring treatment efficacy. The global market of innovative cancer diagnostics is estimated to be $2.5 billion, with CAGR of 45%.
THE TEAM /
ANATOLY MELNIKOV,
Project Director. Over 10 years of research in the project subject matter, several patents, and dozens of publications.
EGOR MELNIKOV,
CEO.
Founder of several successful startups.
GEORGY NIKITIN,
Commercial Director. Private equity fund investment department manager.
VIKTOR LEVENSON,
Scientific Consultant. Co-founder of USBiomarkers.
DIAGNOSIS OF ONCOLOGICAL
DISEASES VIA ANALYSIS OF DNA
CIRCULATING IN BLOOD PLASMA (M-TEST)
BIOMARKER-RU LLC
CONTACTS /
Moscow
Egor Melnikov
+7(495)502-2196
me@l27.ru,
biomarker.ru@gmail.com
www.bio-marker.ru,
www.мтест.рф
(under construction)
M-TEST early in vitro cancer diagnosis

73
INNOVATIVE TEST SYSTEMS FOR
DIAGNOSING ONCOLOGICAL DISEASES BASED ON INDEPENDENTLY DEVELOPED AND PRODUCED ANTIBODIES AGAINST
NEW TUMOR MARKERS
The new test systems will perform diagnosis using peripheral blood serum and will not require a biopsy, which will clearly improve the patient’s quality of life.
Development of novel monoclonal antibodies and innovative noninvasive tests that improve the diagnosis of several types of malignant tumors for which there are currently no simple diagnostic methods.
ACHIEVED RESULTS /
Increased expression of several new markers for gliomas and glioblastomas has been shown.
MARKET POTENTIAL /
The market of tests to determine tumor molecular markers was worth $150 billion in 2010. This segment is expected to grow to $300 billion by 2015.
THE TEAM /
ALEXEY GRACHEV,
Doctor of Biology,CEO;
YULIA KZHYSHKOVSKA,
Doctor of Biology, Professor,
Project Director;
OLGA KOVALEVA,
PhD in Biology;
VASILY KHOMENKOV,
PhD in Biology.
CONTACTS /
Moscow
Alexey Grachev
+7-(499)-645-50-45
info@primebiomed.ru
www.primebiomed.ru
PRIMEBIOMED LLC

74
NEW TYROSINE KINASE INHIBITORS
AS POTENTIAL ANTI-CANCER DRUGS
PF-114 is effective in treating all known mutational resistant forms of Ph+ leukemias and has a high selectivity
of action.
PF-114 is a next-generation targeted inhibitor of Bcr/Abl for treating Ph+ leukemias.
ACHIEVED RESULTS /
The efficacy of PF-114 has been confirmed in in vitro and in vivo models of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemias, including the most resistant forms of the disease with the T315I mutation. The drug’s good safety profile has been confirmed in in vivo toxicology experiments.
MARKET POTENTIAL /
The new drug has the potential to take up to a third of the global market for treating resistant forms of Ph+ leukemias.
THE TEAM /
GHERMES CHILOV,
PhD in Chemistry, CEO.
The team of developers includes specialists in medicinal chemistry, leukemia biology, and preclinical studies.
FUSION PHARMA LLC
CONTACTS /
Moscow
Ghermes
Chilov
+7 (499) 135 53 13
ghermes@
ruspharmtech.ru
ul. Generala
Dorokhova,
18, build. 2

75
The screening system at the leading cancer treatment establishments of the country will enable to increase cancer detectability. More than 150 major medical institutions of the Russian Federation may be equipped in the initial phase.
The hardware and software complex being developed will become a centralized self- learning databank of known neoplasms with the feature of simultaneous connection of the required number of subscribers.
ACHIEVED RESULTS /
The project undergoes the phase of working design documentation development.
MARKET POTENTIAL /
The project product market capacity in Russia may be up to 10,000 user complexes (in 2015); the price of one user complex will be RUB 1.5 mln. The project profit may total up to RUB 15 bln within 2015–2025.
THE TEAM /
IGOR OSTROMETSKY,
CEO.
PROJECT PARTNERS:
JSC NPO RusBITech;
N.N. Blokhin Russian Cancer Research Center of RAMS;
Ivanovo Medical Academy;
Yaroslavl Cancer Center;
Medical University (Graz, Austria);
N. Narimanov Medical University of Azerbaijan(Baku, Azerbaijan).
DEVELOPMENT OF A HARDWARE
AND SOFTWARE SYSTEM AIMED AT
DETERMINING OF MALIGNANT TUMOR SPREAD BY MEANS OF THE FLOW
SCREENING METHOD
RUSBITECH JEMIS LLC
CONTACTS /
Moscow
Igor Ostrometsky
+7 (495) 648 15 33
mav@rusbitech.ru
Bldg. 11, 26
Varshavskoeshosse,
117105 Moscow, Russia
www.rusbitech.ru

76
The created products, as oligonucleotides, represent a new solution to treating inflammatory reactions, pain syndromes, severe infections, immune disorders, and other pathological conditions. Their advantages are:
- high safety;
- fundamentally novel (first-in-class) mechanism of action with no analogs on the market;
- high relative efficacy.
The project will involve conducting clinical and other studies of first-in-class oligonucleotide molecules that influence on the gene expression and have anti- inflammatory and regenerative action for treating poorly healing ulcers. This is the first drug in the world being developed to treat the stated diseases; its mechanism of action is based on inhibiting expression of the gene that codes connexin 43, which prevents the spread of disease and facilitates tissue regeneration. Development of this drug involves a nanotechnology component.
ACHIEVED RESULTS /
Multiple pilot and preclinical studies have demonstrated that the new molecules have molecular mechanisms of action, are selective, and have moderate or no side effects. The drug candidate is currently in phase 2b clinical trials for study as a drug to treat trophic venous leg ulcers and diabetic foot ulcers. Data from completed comparative clinical trials have demonstrated significant superiority of results achieved using the drug as compared to analogs already available on the market.
MARKET POTENTIAL /
According to forecasts, the global market of drugs to heal chronic ulcers will reach 1 billion dollars by 2020. The market of the drug in Russia will be worth 38–50 million dollars by 2022.
THE TEAM /
V. Gurdus: General Director
F. Egros: CEO of NovaMedica
M. Getman: NovaMedica Innotech Executive Director, NovaMedica Vice President for R&D and Regulatory Affairs
K. Grin: Project Scientific Director
University of Auckland, New Zealand.
NEW CLASS OF DRUGS BASED
ON OLIGONUCLEOTIDES WITH
ANTI-INFLAMMATORY
AND REGENERATIVE ACTION
NOVAMEDICA INNOTECH LLC
CONTACTS /
Moscow
Mikhail Getman
info@novamedica.com
125047, Russia,
Moscow,
1-ya Brestskaya,29
www.novamedica.com
IMMUNO-THERAPEUTICS, THERAPEUTICS FORINFLAMMATION

77
ORIGINAL PEPTIDE DRUGS FOR A TREATMENT OF NEUROLOGICAL
AND AUTOIMMUNE DISEASES
The technologies for obtaining the pharmaceutical substances of peptide drugs with a wide range of indications for clinical use have been developed. Modern methods of synthesis and purification were used.
The lines of original «non-invasive» forms of peptide drugs and ways of their delivery to the body have been developed.
ACHIEVED RESULTS /
Stemokine has been approved for the entrance to the Russianmarket.
IBCh-07Me passes Phase I studies.
IBCh-05OH passes Phase I studies.
C12-OB passes pre-clinical studies.
Thymodepressin was approved for sale in theRussian Federation.
MARKET POTENTIAL /
New original peptide drugs are intended for a treatment of a number of socially significant diseases. These drugs are desired in the global pharmaceutical market.
THE TEAM /
VLADISLAV DEIGIN,
Doctor of Biological Sciences,
PhD inChemical Sciences, Prof., CEO.
VADIM IVANOV,
member of RAS, Doctor of Chemistry, Prof., Project
Research Manager.
PHARMA BIO
CONTACTS /
Moscow
Vladislav Deigin
vdeigin@pharmabio.ru
www.pharmabio.ru

78
The drug solves a key problem of anti-inflammatory therapy such as the presence of a dangerous ulcerogenic side effect, which is the frequent cause of hospitalization and death for many patients taking NSAIDs.
The core of the solution is the technology of selective inhibition of the inducible NO-synthase (iNOS). This isoform of the enzyme catalyzes the excessive production of nitric oxide, which is one of the key mechanisms of pathological inflammation.
ACHIEVED RESULTS /
Preclinical studies (toxicology, pharmacodynamics, pharmacokinetics, the technology of synthesis of the substance, the pharmaceutical development of the substance and drug formulation).
MARKET POTENTIAL /
The target market of the product is the segment of non-steroidal anti- inflammatory drugs (NSAIDs) that includes drugs with analgesic, antipyretic and anti- inflammatory effects.
THE TEAM /
NATALIA CHALDYSHEVA,
CEO;
NATALIA BELSKAYA,
Director of Preclinical Research;
SERGEY ZAITSEV,
Head of Department of Medicinal Chemistry;
JOSEPH SCHWARZ,
Consultant on the Development of Pharmaceutical Substances and Finished Dosage Form of a New Drug.
DEVELOPMENT OF INNOVATIVE
ANTI-INFLAMMATORY DRUG WITH
A NEW MECHANISM OF ACTION
INPHARMA CJSC
CONTACTS /
Tomsk
Natalia
Chaldysheva
+7 (3822) 24 87 13
nattavi1@gmail.com
Russia, Tomsk Region,
Tomsk, ul. Elizarovykh, 79/4

Sk Top Bio Startups

Recommended

Recommended

More Related Content

What's hot

What's hot (19)

Similar to Sk Top Bio Startups

Similar to Sk Top Bio Startups (20)

Recently uploaded

Recently uploaded (20)

Sk Top Bio Startups